Finnish Biotech Secures U.S. Patent for Ivermectin-based Nasal Spray to Take on COVID-19 in Low-to-Middle-Income Countries (LMICs)
A biotech venture based in Turku, Finland, called Therapeutica Borealis just secured a patent from the United States Patent and Trademark Office (USPTO) for its COVID-19 therapy based on ivermectin and a few other notable therapies: hydroxychloroquine and aprotinin. Developed as a nasal spray...
trialsitenews.com
Finnish Biotech Secures U.S. Patent for Ivermectin-based Nasal Spray to Take on COVID-19 in Low-to-Middle-Income Countries (LMICs)
Office (USPTO) for its COVID-19 therapy based on ivermectin and a few other notable therapies: hydroxychloroquine and aprotinin
Finnish firm earns US patent for Covid drug containing ivermectin and hydroxychloroquine
The Turku company says its nasal spray delivers low, safe doses of hydroxychloroquine, ivermectin and aprotinin.
yle.fi
Finnish firm earns US patent for Covid drug containing ivermectin and hydroxychloroquine
The Turku company says its nasal spray delivers low, safe doses of hydroxychloroquine, ivermectin and aprotinin.
"This medication would not do away with the need to get vaccinated, but it would prevent people from being infected at a location where the risk exists," Vaananen said. "It can work prophylactically on short notice, and within limited time."
"It would not impact the virus itself," so whether there are variants or not, it is not crucial, said Vaananen, who is also a professor of cell biology. "Instead, the medication impacts the cellular structures the virus uses to enter the body, so a change in the virus would not change the way it uses the cellular mechanisms," he added.
Active ingredients of the medicine are aprotinin, hydroxychloroquine, and ivermectin, which are known as effective drugs for the treatment and prevention of COVID-19
Saksela’s team has had a patent-free COVID-19 vaccine ready since May 2020, which they dubbed “the Linux of vaccines” in a nod to the famous open-source operating system that also originated from Finland. The work is based on publicly available research data and predicated on the principle of sharing all new findings in peer-reviewed journals.
But instead of exploring the potential of intellectual property–free research, Finland, like other Western countries, has continued to follow the default policy of the last several decades: to lean fully on Big Pharma.
Finland Had a Patent-Free COVID-19 Vaccine Nine Months Ago — But Still Went With Big Pharma
A team of leading Finnish researchers had a patent-free COVID-19 vaccine ready last May, which could have allowed countries all over the world to inoculate their populations without paying top dollar. Yet rather than help the initiative, Finland's government sided with Big Pharma — showing how a...
jacobinmag.com
Finnish company announces development of nasal spray against COVID-19
Therapeutica Borealis Oy, COVID-19, nasal spray
